Cellular Biomedicine Group (CBMG) operates facilities in China and complies with FDA and international standards partnering with U.S., European and Asian cell therapy companies. The life sciences sector is heating up on Wall Street with innovation and deals. Cellular Biomedicine recently acquired Immune Cell Therapy Technology and its U.S. patents for $3.28 million. At the same time, the company discontinued the consulting segment of their business. Cao spoke to TheStreet's Susannah Lee on the company's expansion plans and how stem cell research works for a China based company.

More from Video

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home